{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PCD&page=5", "query": { "intervention": "PCD", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 456, "total_pages": 46, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PCD&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PCD&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T04:55:39.801Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03095352", "title": "Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Chest Wall Disease" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Laura Huppert, MD, BA", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2017-09-02", "completion_date": "2024-11-30", "has_results": true, "last_update_posted_date": "2025-12-22", "last_synced_at": "2026-10-22T04:55:39.801Z", "location_count": 7, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03095352" }, { "nct_id": "NCT06644768", "title": "A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer", "Lung Cancer" ], "interventions": [ { "name": "valemetostat tosylate", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 137, "start_date": "2024-10-30", "completion_date": "2030-04-30", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-10-22T04:55:39.801Z", "location_count": 11, "location_summary": "La Jolla, California • Los Angeles, California • Jacksonville, Florida + 7 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06644768" }, { "nct_id": "NCT06445972", "title": "Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastroesophageal Junction", "Gastroesophageal Adenocarcinoma", "Esophageal Neoplasms", "Esophageal Cancer" ], "interventions": [ { "name": "Ramucirumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Sacituzumab Tirumotecan", "type": "BIOLOGICAL" }, { "name": "Rescue Medications", "type": "DRUG" }, { "name": "HER3-DXd", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2024-08-07", "completion_date": "2030-08-08", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-10-22T04:55:39.801Z", "location_count": 8, "location_summary": "Tucson, Arizona • Los Angeles, California • Louisville, Kentucky + 5 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "East Syracuse", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06445972" }, { "nct_id": "NCT01087151", "title": "A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "ABT-263", "type": "DRUG" }, { "name": "rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 118, "start_date": "2010-08", "completion_date": "2012-06", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-10-22T04:55:39.801Z", "location_count": 48, "location_summary": "Alhambra, California • Antioch, California • Berkeley, California + 38 more", "locations": [ { "city": "Alhambra", "state": "California" }, { "city": "Antioch", "state": "California" }, { "city": "Berkeley", "state": "California" }, { "city": "Burbank", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01087151" }, { "nct_id": "NCT06545955", "title": "A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-muscle Invasive Bladder Cancer With Carcinoma in Situ" ], "interventions": [ { "name": "Nadofaragene Firadenovec", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ferring Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2024-10-01", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-22T04:55:39.801Z", "location_count": 40, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06545955" }, { "nct_id": "NCT04332653", "title": "NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Any Advanced Solid Tumors", "Triple Negative Breast Cancer", "Non Small Cell Lung Cancer", "Small Cell Lung Cancer", "Microsatellite Stable Colorectal Cancer", "Pancreatic Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "NT-I7", "type": "DRUG" }, { "name": "pembrolizumab (KEYTRUDA®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NeoImmuneTech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 215, "start_date": "2020-06-10", "completion_date": "2025-01-13", "has_results": true, "last_update_posted_date": "2026-03-09", "last_synced_at": "2026-10-22T04:55:39.801Z", "location_count": 8, "location_summary": "Tampa, Florida • Detroit, Michigan • St Louis, Missouri + 5 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04332653" }, { "nct_id": "NCT00762801", "title": "Studies on the Expression and Functions of RLIP76 in Blood Samples of Healthy Human Subjects", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Healthy" ], "interventions": [], "intervention_types": [], "sponsor": "University of North Texas Health Science Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2008-09", "completion_date": "2011-09", "has_results": false, "last_update_posted_date": "2016-10-26", "last_synced_at": "2026-10-22T04:55:39.801Z", "location_count": 2, "location_summary": "Fort Worth, Texas", "locations": [ { "city": "Fort Worth", "state": "Texas" }, { "city": "Fort Worth", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00762801" }, { "nct_id": "NCT03156114", "title": "This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Ezabenlimab", "type": "DRUG" }, { "name": "BI 754111", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 172, "start_date": "2017-06-13", "completion_date": "2023-06-06", "has_results": true, "last_update_posted_date": "2026-01-26", "last_synced_at": "2026-10-22T04:55:39.801Z", "location_count": 6, "location_summary": "Miami, Florida • Sarasota, Florida • Hackensack, New Jersey + 3 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03156114" }, { "nct_id": "NCT05420948", "title": "A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer", "Head and Neck Squamous Cell Carcinoma", "Head and Neck Neoplasms", "Head Cancer", "Throat Carcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2022-10-17", "completion_date": "2026-12-01", "has_results": false, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-10-22T04:55:39.801Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05420948" }, { "nct_id": "NCT05025085", "title": "A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "AGEN1777", "type": "DRUG" }, { "name": "a PD-1 inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Agenus Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2021-10-04", "completion_date": "2024-04-01", "has_results": false, "last_update_posted_date": "2025-10-15", "last_synced_at": "2026-10-22T04:55:39.801Z", "location_count": 11, "location_summary": "Grand Rapids, Michigan • Southfield, Michigan • Cincinnati, Ohio + 4 more", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Southfield", "state": "Michigan" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05025085" } ] }